Related Experiment Videos
[Glucocorticoid therapy for children with idiopathic nephrotic syndrome]
1Department of Pediatrics, National Nishi-Sapporo Hospital, Japan.
Insights
Lower dose prednisolone is effective for childhood nephrotic syndrome, reducing adverse effects. This finding supports optimizing glucocorticoid therapy for better patient outcomes.
Area of Science:
- Pediatric Nephrology
- Pharmacology
Context:
- Idiopathic nephrotic syndrome (INS) in children requires effective treatment.
- Glucocorticoids are a primary therapy, but optimal dosing and equivalent effects of different agents are debated.
Purpose:
- To evaluate the efficacy of a lower dose of prednisolone in initial treatment for childhood INS.
- To compare the effectiveness of different glucocorticoids based on their immunosuppressive properties.
Summary:
- A lower dose of prednisolone (40 mg/m2 body surface area) demonstrated comparable efficacy to the standard ISKDC protocol (60 mg/m2 body surface area) in achieving proteinuria-free status.
- The study suggests that equivalent anti-inflammatory effects of glucocorticoids may not fully translate to equivalent immunosuppressive effects in treating INS.
- Reducing the glucocorticoid dose could mitigate adverse effects associated with long-term steroid use.
Impact:
- Provides evidence for optimizing initial glucocorticoid therapy in pediatric nephrotic syndrome, potentially reducing side effects.
- Highlights the need for further fundamental analysis of empirically proven evidence in glucocorticoid treatment for INS.
- Contributes to the understanding of glucocorticoid equivalency and its application in managing childhood nephrotic syndrome.
Abstract:
The glucocorticoid treatment of patients with idiopathic nephrotic syndrome in children was reported especially focused upon the dose of initial treatment and different effect of various glucocorticoids if they were used equivalently. It appeared that lower dose prednisolone; 40 mg/m2 bsa (body surface area) was also effective same as 60 mg/m2 bsa of protocol of ISKDC (International Study of Kidney Disease in Children) for the initial treatment if time for free proteinuria was taken as index. Therefore, it was considered favorable that we could use lower dose to avoid various adverse effects of glucocorticoids. Clinically it was felt that some different effects were present despite of their equivalent use. The equivalency of various glucocorticoids was based upon anti-inflammatory effect experimentally. The etiology of idiopathic nephrotic syndrome has not been well known, however some sort of immune disorder has been thought most important. Therefore, it might be acceptable if effect of glucocorticoid treatment of nephrotic syndrome is evaluated on the basis of immunosuppression. It is hoped that these empirically proven evidence should be analysed fundamentally in the near future.